The European Commission’s science and knowledge service

Joint Research Centre

Options for Synergies between ESIF and Horizon 2020

Nida Kamil Ozbolat

European Commission JRC.B3 Territorial Development

Breda, 21st of June 2018

Stairway to Excellence (S2E)

Targeted support to S3 implementation

Five closely complementary JRC activities

Targeted Support to Regional Innovation Eco-systems

RIS3 Support

to Lagging

Regions

RIS3 Support

to Romania

Higher

Education +VET

in Smart

Specialisation

Stairway to

Excellence

European

Parliament

DG REGIO

European

Parliament

DG REGIO

DG EAC

DG EMPL

European

Parliament

DG REGIO

2016-2018+ 2016-2018+ HESS2 - 2017-8+ S2E –3 2017-8+

Coal and

industrial

transition

regions

DG ENER

DG REGIO

2018+

S2E III - Closing the innovation gap & Achieving excellence in EU MSs & Regions (extended to EU28)

Governance of

PROs

Training for MAs

and RIS3 teams

International

Project

Development

Labs

Multi-level

governance of

synergies

Capacity building for

increased H2020 participation Exploring new scenarios for

combining funding sources

Funding guidance

Collaboration

between

MAs and JUs

Collaboration

between

MAs and KICs

under RIS3

Explore other

synergies

Rationale: Innovation gap in EU

Regional R&D Intensity as a % of GDP

Evolution of the Share of EU FP Contribution Received

Addressing the innovation gap

Total H2020 contribution ESIF contribution in R&I

ANALYSIS: discovery of the socio-economic and R&I engines of regional growth

PROCESS: governance, stakeholder involvement, institutional setting.

VISION/OBJECTIVES: common shared goals.

PRIORITIES: activities/projects/actions to focus on.

POLICY MIX: policy instruments and interactions.

MONITORING: for selection & assessment processes.

"RIS3" approach

Snapshot for health: RIS3 & H2020

Leading region

H2020 in EU.3.1. - Health, demography

and wellbeing

London [UKI] 188.90 M

West-Nederland [NL3] 187.61 M

Ile De France [FR10] 122.13 M

Cataluña [ES51] 70.38 M

South East (England) [UKJ] 66.35 M

Berlin [DE3] 58.08 M

Stockholm [SE11] 53.72 M

Baden-Wurttemberg [DE1] 51.90 M

Nordrhein-Westfalen [DEA] 51.68 M

Comunidad De Madrid [ES30] 51.58 M

Hovedstaden [DK01] 51.40 M

Southern and Eastern [IE02] 49.15 M

Bayern [DE2] 45.12 M

Vlaams Gewest [BE2] 41.38 M

Oost-Nederland [NL2] 37.14 M

Health priorities in Eye@RIS3

Total H2020 contribution in health

Synergies: Rationale & Concepts

H2020 ESIF

International consortia (non-territorial)

Single beneficiaries (place-based)

Competition for funds Pre-allocated

Centralised management Co-managed with MSs

Annually adjusted WPs 7-year-OP

Research excellence (with individual R&I projects)

Socio-economic development (focusing on R&I capacities)

Not counted for EU State Aid purposes

Counted for EU State Aid purposes

How to achieve synergies?

• … i.e. regarding the projects

• Sequential/Successive projects that build on each other

• Alternative funding: Take up high quality project Horizon 2020 proposals for which there is not enough budget available and implement via ESIF

• Parallel projects that complement each other

• Cumulative funding: Bringing together Horizon 2020 and ESIF money in the same project

Examples of synergies: Summary

• Case studies – good practices achieved synergies between ESIF and Horizon 2020 – available at S2E webpage

• 6 Developed in-house (JRC in Seville) and 19 by national experts

• Aim to:

• Identify the facilitating mechanisms and the bottlenecks in the implementation of synergies

• Identify specific rules and legal aspects at different policy levels that may enhance or limit the creation of such synergies

• Provide suggestions to improve the synergies

• Overall to support policy learning

More details at: http://s3platform.jrc.ec.europa.eu/synergies-examples

Example I: Centre for Nanohealth (UK) (Sequential upstream synergies)

Background Factors facilitating synergies Limiting factors

- Started with ERDF Convergence Programme ~10M€ ERDF funding (2009-2015) - Exploited the R&I capacity of West Wales and the Valleys - Also aims to promote SMEs to work on the development of new healthcare technologies

- Strong institutional support – Department for Research and Innovation (financial, administrative and business development) - Active regional authority and financial support for proposal preparation

- Administrative complexity of combining different funding sources – also time frames. - General issue related to sustainability of the facility

Diagram

SF Project 1: Research centre

in nanohealth

Including acquisition of: Nano/Micro Fabrication Facility Printing Equipment

AEROSOL PRINTER

BIOPLOTTER

Rheology Equipment Molecular & Tissues Culture Facilities Cell Imaging Suite Characterisation Equipment

2009-2015 (£10mil ERDF and

£11.3mil local funding)

FP7 Project 1: SME FP7 2008 – Ambulatory Magneto-

Enhancement of Transdermal High Yield Silver

Therapy (AMETHYST)

National Project: Engineering and Physical Sciences

Research Council (EPSRC), UK call - Nanoparticle

Cytometrics: a quantitative analysis of the toxic

effect of nanoparticles

Other Projects

•INTERREG Ireland and Wales - Celtic Alliance for Nanohealth (CAN)

•REGPOT New Molecular Solutions in Research and Development for Innovative Drugs (INNOMOL) – Realise the research potential of Institut Ruđer Bošković (Zagreb)

•National Funding - EPSRC Building Global Engagements in Research

•Many links with local businesses

Example II: JSC Vittamed - absolute intracranial pressure (aICP) measurement device (LT)

(Sequential downstream synergies)

Background Factors facilitating synergies Limiting factors

- FP7 Brainsafe (I) – started Oct 2009 ~ developed aICP measurement device - FP7 Brainsafe (II) – started Sept 2012 ~ device upgrated - “Vittamed" (2014) export development and promotion in foreign markets: ~64K€ ERDF

- Selection and focus on most appropriate funding - Planned approach - Market-oriented research

- Excessive accounting and procurement procedures. - long delays to authorise minor changes to projects

FP7 Project1: “Brainsafe” FP7 Project 2: “Brainsafe II”

SF Project1: ““JSC “Vittamed" export development and promotion in foreign markets” (€63,886.7). Product presentation for foreign markets are supported.

Example III: SME Rhenovia-Pharma – Alsace (FR) (Sequential and parallel funding & Upstream and downstream)

Background

- Rhenovia Pharma is an R&I pharmaceutical-biotechnology - Established in 2007 – focused on Biosimulation & Drug and Trans-dermal therapy - Dependent on public support due to limited resources – uses all (national, FP, SF)

Factors facilitating synergies

- Funding opportunities information & Networking support from cluster Alsace Biovalley - Alsace Innovation Agency and the H2020 NCP – Toolbox for funding - Systemic monitoring of funding opportunities

Limiting factors

- Lack of tailored support for activities such as proposal writing and IPR. - Loss of time due to administrative procedures – also prevents focus on scientific aspects of a project

National Project 1: Project selected by the Cluster Alsace Biovalley and funded by the Ministry of Economy RHENEPI Development of a biosimulation platform for epileptic crisis to identify and test new therapies (2010-2012, 2.5 M€)

ERDF Project: Development of a biosimulation platform (2010, Total cost: 390 K€ ERDF funding 56 K€)

FP7 Project 1: MOD ENP TOX Application of Biosimulation (2013-2015, 1.4 M€)

EUROSTARS programme: ALTHERAS Development of a new medical treatment tool (2008-2011, 913 K€)

National Project 3: French Worldwide Innovation Challenge SMARTT e-Patch New electronic transdermal patch (2014-? , 200 K€+ ?)

FP7 Project 2: SELFMEM Application of filtration technology (2009-2012, 5.2 M€)

National Project 2: RAPID programme on dual technologies RHETOX Development of a biosimulation platform to analyse the impact of neurotoxins on brain function antidotes (2011-2014, 1.1 M€)

2008 2015

Tran

s-de

rmal

pat

ch

Bio

sim

ulat

ion

plat

form

Example IV: ITME - Research in novel materials with unusual electromagnetic properties (PL)

(Sequential and parallel downstream synergies)

Background Factors facilitating synergies Limiting factors

- Institute of Electronic Materials Technology (ITME): initial research through FP funding - Subsequent SF for practical applications and industrial collaborations - National funds & funding from US Air Force

- Creativity of researchers - Careful selection of FP consortium partners - Support of the Brussels-based PolSCa (Polish Science Contact Agency)

- H2020 regulations on researcher salaries. - SF applications not aligned to FP7/H2020 - Administrative burden

Diagram of chronology of the main projects involved in synergies

SF Project 1: “Self-organization approach towards photonics/optoelectronics” (POIG TEAM), empirical research of materials with potential industrial applications (2009-2013, 0.5m EUR)

SF Project 2: “TOP 500 Innovators” (POKL), training in commercialisation of research results (2012)

FP Project 1: “METAMORPHOSE” (FP6 NoE), networking researchers in the emerging field of metamaterials (2004-2008, 4.4m EUR) FP Project 2: “ENSEMBLE” (FP7 NMP), empirical research of metamaterials (2008-2012, 5m EUR)

National Project 1: “New generation plasmonic materials” (MAESTRO, 2012-2016, 0.7m EUR)

National Project 2: “NOE”

(US Air Force Office for Scientific Research MURI,

2014-2017)

National Project 3: “Eutectics and

metamaterials at a crossroads” (HARMONIA,

2014-2018, 0.5m EUR)

Example V: Central European Institute of Technology (CEITEC) (CZ)

(Sequential upstream synergies)

Background

- Centre of scientific excellence in the fields of life sciences and advanced materials and technologies - Research facilities created with an investment of around 300 M€ (85% from ERDF) - Various funding mechanisms subsequently combined in a complementary manner

Factors facilitating synergies

- Strategic planning & engagement of regional actors - Attracting best scientists – transparent and fair carrier opportunities, cutting-edge equipment, focus on high-quality research and international mobility - Networking - Science support office

Limiting factors

- Complex institutional structure - Communication with local authorities & NCPs - Administrative burden (especially in auditing)

Other synergies: EU bodies and platforms

Joint Undertakings - Innovative Medicines 2 (IMI2)

• IMI1 (2008) and IMI2 (2014): Improve health by speeding up the development of innovative medicines and treatments (vaccines, antibiotics etc.), based on the social needs

• Facilitating collaboration among key actors & Provide funding by calls (open and competitive)

• Aligning their activities with national and regional MAs and RIS3 implementation bodies

Joint workshop organised by JUs and S2E focusing on synergies between JUs and ESIF in RIS implementation, took place in Brussels on 7th of March 2018

EIT Health Knowledge and Innovation Communities (KICs)

• EIT Health (2010): Promote healthy living & Support active ageing & Improve healthcare

• Organised in 16 MSs and 7 macro-regions with more than 150 partner organisations – also extended the scheme towards lagging regions (EIT RIS)

• Supports in knowledge triangle: Educational programmes for student, executives, professionals and innovators; Support to incubate/validate/scale; Innovation by Ideas/Design/Wild Card

Joint event organised by EIT Climate-KIC and S2E focusing on collaboration opportunities between RIS3 and EIT RIS, took place in Ljubljana on 20/03/2018

Issues and barriers for synergies

Quality of Governance

•A long-term strategic plan with a shared vision

•Coordination and communication between main actors

•Accessing the necessary information on a timely manner

•Administrative burden and complicated procedures

Capacity Building

•Lack of capacity (infrastructure, HRs, etc.) for excellent research

•Human capital, incl. researchers and managers/administrative support

•Active interaction between academia and business

•Participation in Framework Programmes

Innovation

•Different natures/legal framework of funding sources

•Continuous and sustainable financing

•Public-private collaboration at international level

•Align RIS3 and research in where comparative advantage exist

¡THANK YOU!

Stairway to Excellence (S2E): http://s3platform.jrc.ec.europa.eu/stairway-to-excellence